Combination therapy for prostate cancer using botanical compositions and bicalutamide
A prostate cancer and composition technology, applied in the direction of drug combination, plant raw materials, plant/algae/fungus/moss components, etc., can solve the problems of prostate cancer that cannot be cured
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
example 1
[0114] Example 1: Method for preparing plant extract
[0115] Compositions of the invention may be administered as a dried herb. Herbal preparations contain phytochemicals, some of which are soluble in aqueous media while others are relatively more soluble in organic (alcoholic, lipid) media. For the ability to extract active ingredients from medicinal herbs, different extraction methods were used and tested. Extraction methods include: aqueous (hot water) extraction; organic (lipid fraction) extraction; non-alcoholic organic (ethyl acetate) extraction; and alcoholic (ethanol) extraction.
[0116] The product is prepared from the herb or herb blend by extraction with a solvent (hot water, 80% ethanol or ethyl acetate) at reflux for 30-60 minutes, separated by filtration to obtain a filtrate, and air-dried for further use. analyze. These filtrates were combined, diluted or concentrated prior to determination of activity.
example 2
[0117] Example 2: OMN54 against prostate cancer cells and (bicalutamide) combination
[0118] OMN54 with The combination of (bicalutamide) achieved a greater anti-tumor growth effect than OMN54 alone or bicalutamide in C4-2 castration-resistant prostate cancer cells in vitro ( figure 1 ). Treatment with either bicalutamide (10 μM) or OMN54 (10 μg / ml) alone had minimal inhibitory effect on C4-2 cells, however, the combination of OMN54 (10 μg / ml) and bicalutamide (10 μM) at 48 h Significantly inhibited cell growth (see figure 1 ).
[0119] Effect of these two drugs and their combination on androgen receptor (AR) expression. AR protein expression was reduced in the OMN54-treated group, but not in the control group. Compared with OMN54 alone or bicalutamide group, in OMN54 and AR expression was further reduced in the (bicalutamide) combination group (see figure 2 ).
example 3
[0120] Example 3: Effect of OMN54 and bicalutamide treatment on AR expression
[0121] figure 2 The effect of OMN54 and bicalutamide treatment on AR expression in C4-2 cells is shown by Western blot analysis.
[0122] Using adult plant experiments, it was found that OMN54 and The combination of (bicalutamide) achieved a greater anti-tumor growth effect than OMN54 alone or bicalutamide in C4-2 castration-resistant human prostate cancer cells in vitro ( image 3 ). In this experiment, treatment with bicalutamide (20 μM) proved to have no effect, while OMN54 (50 μg / ml) showed significant inhibitory effect on C4-2 cells, however, OMN54 (50 μg / ml) combined with bicalutamide The combination of amines (20μM) inhibited cell growth even at 24h (see image 3 and Figure 4 ).
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com